The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection

被引：0
|
作者：
Peilong Lai
Xiaomei Chen
Le Qin
Zhiwu Jiang
Chenwei Luo
Xin Huang
Sujing Wu
Wei Ling
Yulian Wang
Jinghua Wang
Chenxin Deng
Lisi Huang
Lingji Zeng
Zesheng Lu
Liye Zhong
Pengjun Liao
Minming Li
Dongmei Chen
Suxia Geng
Ping Wu
Zhaoyang Tang
Duanqing Pei
Xin Du
Peng Li
Jianyu Weng
机构：
[1] Guangdong Academy of Medical Sciences,Department of Hematology, Guangdong Provincial People’s Hospital
[2] University of Chinese Academy of Sciences,State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health
[3] Chinese Academy of Sciences,Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health
[4] University of Chinese Academy of Sciences,undefined
[5] Chinese Academy of Sciences,undefined
[6] Guangdong Zhaotai InVivo Biomedicine Co. Ltd,undefined
来源：
Leukemia | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2790 / 2793
页数：3
相关论文
共 50 条
  • [21] Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection
    Chunmei Yang
    Mixue Xie
    Kaifeng Zhang
    Hui Liu
    Aibin Liang
    Ken H. Young
    Wenbin Qian
    Leukemia, 2020, 34 : 3055 - 3059
  • [22] Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection
    Yang, Chunmei
    Xie, Mixue
    Zhang, Kaifeng
    Liu, Hui
    Liang, Aibin
    Young, Ken H.
    Qian, Wenbin
    LEUKEMIA, 2020, 34 (11) : 3055 - 3059
  • [23] High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma
    Zhang, Xian
    Wang, Lin
    Yang, Junfang
    Li, Jingjing
    Liu, Hongxing
    Li, Jianqiang
    Lu, Peihua
    BLOOD, 2023, 142
  • [24] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [25] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
  • [26] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
  • [27] Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Liu, Yang
    Yan, Zhiling
    Wu, Qingyun
    Chen, Chong
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S49
  • [28] CAR-T Cell Therapy
    Ahmad, Aamir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12)
  • [29] Building safety into CAR-T therapy
    Peters, Daniel T.
    Savoldo, Barbara
    Grover, Natalie S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [30] CAR-T cell therapy
    San Segundo, Lucrecia Yanez
    MEDICINA CLINICA, 2021, 156 (03): : 123 - 125
12345